Key result
Class III antiarrhythmic drugs significantly decreased V1 fibrillatory rate, with amiodarone-treated patients having lower rates than controls (286 vs 371 fpm, P<0.001).
Why the study?
Does time-frequency analysis of surface ECG lead V1 accurately reflect intraatrial fibrillatory activity and detect the effects of class III antiarrhythmic drugs in patients with atrial fibrillation?
Population
55 patients total: 36 patients with drug-refractory atrial fibrillation undergoing catheter-based pulmonary…
Comparison
Time-frequency analysis of surface ECG lead V1… vs Intracardiac recordings for validation; patients…
Design
Cohort
Authors
Loading...
May support noninvasive V1 monitoring of class III effects in AF; leaves open prospective validation before practice change.
Observational (n=55)
Does time-frequency analysis of surface ECG lead V1 accurately reflect intraatrial fibrillatory activity and detect the effects of class III antiarrhythmic drugs in patients with atrial fibrillation?
Absolute Event Rate: 286% vs 371%
p-value: p=<0.001
Time-frequency analysis of surface ECG lead V1 accurately reflects right and left atrial fibrillatory activity and can noninvasively monitor the electrophysiological effects of class III antiarrhythmic drugs.
Husser et al. (2006) conducted an observational in Atrial fibrillation (n=55). Class III antiarrhythmic drugs (amiodarone or dofetilide) vs. No amiodarone or baseline was evaluated on V1 fibrillatory rate (fpm) (p=<0.001). Class III antiarrhythmic drugs significantly decreased V1 fibrillatory rate, with amiodarone-treated patients having lower rates than controls (286 vs 371 fpm, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: